{
    "nctId": "NCT01648608",
    "briefTitle": "Efficacy and Safety of TAC and Exemestane as Neoadjuvant Chemotherapy in the Postmenopausal Women With Breast Cancer",
    "officialTitle": "Study to Assessment the Efficacy and Safety of Joint TAC and Exemestane as Neoadjuvant Chemotherapy in the Postmenopausal Women With Operable Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2, PHASE3",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 600,
    "primaryOutcomeMeasure": "therapeutic assessment",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Karnofsky \u2265 70\n2. Provision of informed consent\n3. Pathological confirmation of invasive ductal carcinoma and estrogen receptor is positive\n4. Tumor stage(TNM):T2-4bN0-3M0\n5. Premenopausal woman\n6. Not previously received treatment with bisphosphonate\n7. Laboratory criteria:\n\n   * PLT \u2265 100\\*109/L\n   * WBC \u2265 4000/mm3\n   * HGB \u2265 10g/dl\n   * GOT,GPT,ALP \u2264 2\\*ULN\n   * TBIL,DBIL,CCr \u2264 1.5\\*ULN\n\nExclusion Criteria:\n\n1. Pregnant or lactation woman\n2. History of organ transplantation\n3. With mental disease\n4. With severe infection or active gastrointestinal ulcers\n5. With severe liver disease (such as cirrhosis), kidney disease, respiratory disease or diabetes\n6. Disease-free period of other malignant tumor is less than 5 years(except cured basal cell skin cancer and cervical carcinoma in situ)\n7. With heart disease\n8. Experimental drug allergy",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}